Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer

PURPOSE: Small cell lung cancer (SCLC) is an aggressive disease with an overall 5-year survival rate of less than 10%. Treatment for SCLC with cisplatin/etoposide chemotherapy (C/E) ± radiotherapy has changed modestly over several decades. The ubiquitin-proteasome system is an underexplored therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Majeed, Safa, Aparnathi, Mansi K., Nixon, Kevin C.J., Venkatasubramanian, Vidhyasagar, Rahman, Fariha, Song, Lifang, Weiss, Jessica, Barayan, Ranya, Sugumar, Vijithan, Barghout, Samir H., Pearson, Joel D., Bremner, Rod, Schimmer, Aaron D., Tsao, Ming S., Liu, Geoffrey, Lok, Benjamin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365348/
https://www.ncbi.nlm.nih.gov/pubmed/35165102
http://dx.doi.org/10.1158/1078-0432.CCR-21-0344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365348/
https://www.ncbi.nlm.nih.gov/pubmed/35165102
http://dx.doi.org/10.1158/1078-0432.CCR-21-0344

Ejemplares similares